GlassScriptPhysician profile
Erin Pettijohn
NPI 1003101429
$10,047.23
in general payments reported to CMS, 2019-2025
72 companies · $2,822 in 2025
The $2,822 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,822 · 2020: $335 · 2021: $25.92 · 2022: $1,486 · 2023: $1,281 · 2024: $2,275 · 2025: $2,822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,377.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $730.50 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $620.19 | 2019-2025 | Enhertu, Onglyza, Calquence |
| Celgene Corporation | $591.70 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Janssen Biotech, INC. | $556.05 | 2019-2025 | Darzalex, Tecvayli, Rybrevant |
| Genentech USA, INC. | $467.52 | 2019-2025 | Polivy, Venclexta, Tecentriq |
| Abbvie INC. | $450.90 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $428.85 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Glaxosmithkline, LLC. | $424.23 | 2020-2025 | Ojjaara, Blenrep |
| Pfizer INC. | $408.08 | 2019-2025 | |
| Incyte Corporation | $395.57 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Takeda Pharmaceuticals U.S.A., INC. | $357.19 | 2019-2025 | Fruzaqla, Iclusig |
| Pharmacyclics LLC, An Abbvie Company | $272.24 | 2019-2023 | Imbruvica |
| Genzyme Corporation | $268.70 | 2019-2025 | |
| Agios Pharmaceuticals, INC. | $260.37 | 2019-2022 | |
| Gilead Sciences, INC. | $237.32 | 2019-2025 | Trodelvy |
Show all 70 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Pettijohn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.